Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Esperion Therapeutics, Inc. - Common Stock (NQ:ESPR)

0.9844 -0.0056 (-0.57%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Esperion Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Esperion Announces Adjournment of 2023 Annual Meeting of Stockholders
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Participate in Jefferies Healthcare Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Reports First Quarter 2023 Financial Results
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Retains Gibson Dunn to Secure $300 Million Payment From DSE; Will Announce First Quarter Financial Results Tuesday, May 9
– Gibson Dunn Files Amended Complaint with Powerful New Evidence – 
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Participate in JMP Securities Life Sciences Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Participate in Bank of America Securities 2023 Health Care Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Report First Quarter 2023 Financial Results May 9, 2023
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces Co-Promotion Agreement With Currax Pharmaceuticals LLC
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Participate in Needham 22nd Annual Virtual Healthcare Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces Closing of $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
From Esperion Therapeutics, Inc.
Via GlobeNewswire
International Lipid Expert Panel (ILEP) Recommends Use of Bempedoic Acid Ahead of PCSK9 Inhibitors in Managing Lipid Disorders and Cardiovascular Risk
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Landmark CLEAR Outcomes Study Demonstrates NEXLETOL® (bempedoic acid) Tablet is the Only LDL-C Lowering Therapy Since Statins to Reduce Hard Ischemic Events in a Broad Population of Both Primary Prevention and Secondary Prevention Patients
Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin 
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Launches New Scientific Website
Designed Specifically for the Scientific and Medical Communities, esperionscience.com Features Information about Esperion’s Landmark CLEAR Outcomes Study, Company Pipeline and More 
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Participate in the Cowen 43rd Annual Healthcare Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
CLEAR Outcomes Company Update Call: Detailed Results Discussion
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces Positive CLEAR Outcomes Results To Be Presented as Late-Breaking Clinical Trial at ACC.23/WCC
– NEXLETOL® (bempedoic acid) is the first ATP citrate lyase inhibitor and first oral non-statin to meet the major adverse cardiovascular events (MACE-4) primary endpoint – 
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Report Fourth Quarter and Full Year 2022 Financial Results February 21, 2023
From Esperion Therapeutics, Inc.
Via GlobeNewswire
RFK Announces Team-Wide Partnership with Esperion Therapeutics; Includes Primary Partnership for Brad Keselowski at the ’23 Daytona 500
NASCAR Champion Brad Keselowski to Run No. 6 NEXLIZET (bempedoic acid and ezetimibe) Ford in Famed Daytona 500 
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Outlines Upcoming Milestones and Announces Preliminary Fourth Quarter 2022 Financial Results
From Esperion Therapeutics, Inc.
Via GlobeNewswire
CLEAR Outcomes Accepted as Late-Breaking Clinical Trial at ACC.23 Annual Scientific Session & Expo together with the World Congress of Cardiology (ACC.23/WCC)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Participate in January Investor Meetings
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL® (bempedoic acid) Meets Primary Endpoint
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Appoints Ben Halladay Chief Financial Officer
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Virtual Research & Development Day to Highlight Pipeline Programs and Scientific Focus
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Participate in Jefferies London Healthcare Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.